A systematic review and meta-analysis of the prevalence of hepatitis B virus infection among pregnant women in Nigeria.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2021
2021
Historique:
received:
11
08
2021
accepted:
14
10
2021
entrez:
29
10
2021
pubmed:
30
10
2021
medline:
15
12
2021
Statut:
epublish
Résumé
Nigeria has a high burden of hepatitis B virus (HBV) infection, commonly acquired through vertical transmission. However, there is a lack of an efficient surveillance system for monitoring and understanding the epidemiology of HBV among pregnant women. Building on a previous review on the prevalence of HBV in Nigeria (2000-2013), we conducted a systematic review and meta-analysis of HBV prevalence among pregnant women in Nigeria. Four electronic databases PubMed, Embase, Global Health, and Scopus were systematically searched from January 2014 to February 2021. We also searched the African Journal Online and manually scanned the reference lists of the identified studies for potentially eligible articles. Observational studies that reported the prevalence of HBsAg and/or HBeAg among pregnant women in peer-reviewed journals were included in the study. We performed a meta-analysis using a random-effects model. We defined HBV infection as a positive test to HBsAg. From the 158 studies identified, 20 studies with a total sample size of 26, 548 were included in the meta-analysis. The pooled prevalence of HBV infection among pregnant women across the studies was 6.49% (95% confidence interval [CI] = 4.75-8.46%; I2 = 96.7%, p = 0.001; n = 20). The prevalence of HBV was significantly lower among pregnant women with at least secondary education compared with those with no education or primary education (prevalence ratio = 0.7, 95% CI = 0.58-0.87; n = 10). However, the prevalence of HBV was not significantly different by age, religion, marital status, or tribe. The prevalence of HBV was not significantly different among pregnant women with previous surgery, blood transfusion, multiple lifetime sex partners, tribal marks, tattoos, scarification, or sexually transmitted infections, compared with those without these risk factors. From a total sample size of 128 (n = 7), the pooled prevalence of HBeAg among HBV-infected pregnant women was 14.59% (95% CI = 4.58-27.99%; I2 = 65.5%, p = 0.01). Subgroup analyses of HBV infection by study region and screening method, and meta-regression analysis of the study year, sample size, and quality rating were not statistically significant. There is an intermediate endemicity of HBV infection among pregnant women in Nigeria. Interventions, such as routine antenatal HBV screening, antiviral prophylaxis for eligible pregnant women, and infant HBV vaccination should be scaled up for the prevention of perinatal transmission of HBV infection in Nigeria.
Sections du résumé
BACKGROUND
Nigeria has a high burden of hepatitis B virus (HBV) infection, commonly acquired through vertical transmission. However, there is a lack of an efficient surveillance system for monitoring and understanding the epidemiology of HBV among pregnant women. Building on a previous review on the prevalence of HBV in Nigeria (2000-2013), we conducted a systematic review and meta-analysis of HBV prevalence among pregnant women in Nigeria.
METHODS
Four electronic databases PubMed, Embase, Global Health, and Scopus were systematically searched from January 2014 to February 2021. We also searched the African Journal Online and manually scanned the reference lists of the identified studies for potentially eligible articles. Observational studies that reported the prevalence of HBsAg and/or HBeAg among pregnant women in peer-reviewed journals were included in the study. We performed a meta-analysis using a random-effects model. We defined HBV infection as a positive test to HBsAg.
RESULTS
From the 158 studies identified, 20 studies with a total sample size of 26, 548 were included in the meta-analysis. The pooled prevalence of HBV infection among pregnant women across the studies was 6.49% (95% confidence interval [CI] = 4.75-8.46%; I2 = 96.7%, p = 0.001; n = 20). The prevalence of HBV was significantly lower among pregnant women with at least secondary education compared with those with no education or primary education (prevalence ratio = 0.7, 95% CI = 0.58-0.87; n = 10). However, the prevalence of HBV was not significantly different by age, religion, marital status, or tribe. The prevalence of HBV was not significantly different among pregnant women with previous surgery, blood transfusion, multiple lifetime sex partners, tribal marks, tattoos, scarification, or sexually transmitted infections, compared with those without these risk factors. From a total sample size of 128 (n = 7), the pooled prevalence of HBeAg among HBV-infected pregnant women was 14.59% (95% CI = 4.58-27.99%; I2 = 65.5%, p = 0.01). Subgroup analyses of HBV infection by study region and screening method, and meta-regression analysis of the study year, sample size, and quality rating were not statistically significant.
CONCLUSIONS
There is an intermediate endemicity of HBV infection among pregnant women in Nigeria. Interventions, such as routine antenatal HBV screening, antiviral prophylaxis for eligible pregnant women, and infant HBV vaccination should be scaled up for the prevention of perinatal transmission of HBV infection in Nigeria.
Identifiants
pubmed: 34714888
doi: 10.1371/journal.pone.0259218
pii: PONE-D-21-25950
pmc: PMC8555786
doi:
Types de publication
Journal Article
Meta-Analysis
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0259218Déclaration de conflit d'intérêts
OAU currently serves as an Academic Editor for PLOS One.
Références
Niger J Med. 2014 Jul-Sep;23(3):248-53
pubmed: 25185383
Hum Antibodies. 2020;28(3):233-243
pubmed: 32333583
Aliment Pharmacol Ther. 2016 Nov;44(10):1005-1017
pubmed: 27630001
Arch Public Health. 2014 Nov 10;72(1):39
pubmed: 25810908
BMJ. 1997 Sep 13;315(7109):629-34
pubmed: 9310563
Infect Dis Obstet Gynecol. 2020 Jun 11;2020:9418475
pubmed: 32577077
Afr J Lab Med. 2019 Jun 27;8(1):622
pubmed: 31309044
J Infect Dis. 1994 Dec;170(6):1418-23
pubmed: 7995980
J Immunoassay Immunochem. 2017;38(6):639-651
pubmed: 29035130
Control Clin Trials. 1986 Sep;7(3):177-88
pubmed: 3802833
Am J Epidemiol. 1998 Mar 1;147(5):478-87
pubmed: 9525535
Stat Med. 2002 Jun 15;21(11):1539-58
pubmed: 12111919
MMWR Morb Mortal Wkly Rep. 2014 Jul 25;63(29):613-9
pubmed: 25055184
J Obstet Gynaecol. 2013 Feb;33(2):155-9
pubmed: 23445138
J Immunoassay Immunochem. 2020 Sep 2;41(5):913-923
pubmed: 32835616
BMC Infect Dis. 2018 Jun 28;18(1):288
pubmed: 29954344
PLoS Med. 2009 Jul 21;6(7):e1000097
pubmed: 19621072
BMJ Open. 2017 Jun 2;7(5):e015845
pubmed: 28576900
Int J Epidemiol. 1991 Jun;20(2):495-503
pubmed: 1917255
Med Sci (Basel). 2017 Oct 18;5(4):
pubmed: 29099040
Wkly Epidemiol Rec. 2009 Oct 1;84(40):405-19
pubmed: 19817017
Scand J Infect Dis. 2003;35(11-12):814-9
pubmed: 14723355
J Epidemiol Community Health. 1985 Jun;39(2):123-8
pubmed: 4009096
Rev Infect Dis. 1989 May-Jun;11 Suppl 3:S574-8
pubmed: 2527402
J Med Virol. 2003 Nov;71(3):360-6
pubmed: 12966540
Clin Infect Dis. 1995 Apr;20(4):992-1000
pubmed: 7795104
BMJ Open. 2014 Nov 11;4(11):e005889
pubmed: 25387757
BMC Infect Dis. 2020 Mar 6;20(1):194
pubmed: 32138677
Niger J Clin Pract. 2015 Mar-Apr;18(2):163-72
pubmed: 25665986
Lancet Gastroenterol Hepatol. 2018 Jun;3(6):383-403
pubmed: 29599078
J Med Virol. 2002 May;67(1):20-6
pubmed: 11920813
Virology (Auckl). 2018 Aug 22;9:1178122X18792859
pubmed: 30150873
Vaccine. 2020 Mar 10;38(12):2734-2740
pubmed: 32007294
Ther Adv Vaccines Immunother. 2020 Jan 16;8:2515135519900743
pubmed: 32002499
Am J Trop Med Hyg. 2016 Oct 5;95(4):902-907
pubmed: 27527630
Lancet Gastroenterol Hepatol. 2017 Feb;2(2):103-111
pubmed: 28403980
J Immunol Sci. 2018 Aug 2;Suppl(5):31-40
pubmed: 30931434
World J Hepatol. 2012 Mar 27;4(3):74-80
pubmed: 22489259
Ann Afr Med. 2016 Jan-Mar;15(1):20-7
pubmed: 26857933
Vaccine. 2012 Mar 9;30(12):2212-9
pubmed: 22273662
Viral Immunol. 2019 May;32(4):186-191
pubmed: 31021251
J Immunoassay Immunochem. 2016;37(1):29-42
pubmed: 25879258
BMC Infect Dis. 2012 Jun 09;12:131
pubmed: 22682147
J Clin Virol. 2018 Dec;109:29-34
pubmed: 30388664
Acta Obstet Gynecol Scand. 2010 Aug;89(8):1024-8
pubmed: 20636241
Trop Med Int Health. 2021 Mar;26(3):316-326
pubmed: 33247862
Pan Afr Med J. 2015 Apr 24;20:406
pubmed: 26301010
J Trop Pediatr. 2015 Dec;61(6):407-13
pubmed: 26411561
Int J Evid Based Healthc. 2015 Sep;13(3):147-53
pubmed: 26317388
BMC Infect Dis. 2018 Jul 11;18(1):322
pubmed: 29996785
Arch Virol. 2018 Feb;163(2):319-330
pubmed: 29063378
Ann Med Health Sci Res. 2014 Nov;4(6):954-8
pubmed: 25506493
Int J STD AIDS. 2021 Aug 13;:9564624211035922
pubmed: 34387113
Niger J Clin Pract. 2015 Nov-Dec;18(6):819-23
pubmed: 26289525
J Med Libr Assoc. 2019 Jan;107(1):57-61
pubmed: 30598649
Int J Med Sci. 2005;2(1):50-57
pubmed: 15968340
J Antimicrob Chemother. 2015 Feb;70(2):396-404
pubmed: 25362571
Epidemiol Rev. 2006;28:112-25
pubmed: 16754644
N Engl J Med. 2016 Jun 16;374(24):2324-34
pubmed: 27305192
Virol J. 2011 Jan 12;8:12
pubmed: 21226907
Vaccine. 2019 Jan 7;37(2):223-225
pubmed: 28743487
Int J Infect Dis. 2021 Mar;104:276-281
pubmed: 33359947
Am J Trop Med Hyg. 2018 Aug;99(2):428-434
pubmed: 29869595
N Engl J Med. 2004 Dec 30;351(27):2832-8
pubmed: 15625334
Vaccine. 2019 Oct 31;37(46):6894-6899
pubmed: 31562005
BMJ. 2003 Sep 6;327(7414):557-60
pubmed: 12958120